Recursion Pharmaceuticals has been granted a patent for compounds of Formula (I) and Formula (II) for treating diseases. The patent includes pharmaceutical compositions and methods for treatment. GlobalData’s report on Recursion Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Recursion Pharmaceuticals, Vehicle driver physiological monitoring was a key innovation area identified from patents. Recursion Pharmaceuticals's grant share as of February 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11919868B2) discloses a compound of Formula (I) and its various stereoisomers, tautomers, and pharmaceutically acceptable salts. The patent also covers specific compounds represented by Formulas (Ia) to (If) and Formula (II) along with their variations. Additionally, the patent includes a pharmaceutical composition containing the compound of claim 1 and a method for making the compound. Furthermore, the patent describes a method for treating a C. difficile infection by administering the compound along with other therapeutic agents like vancomycin, fidaxomicin, or metronidazole.
The patent emphasizes the potential therapeutic applications of the disclosed compound in treating C. difficile infections. By administering the compound, either alone or in combination with other agents, a therapeutically-effective treatment can be provided to individuals suffering from such infections. The patent also highlights the structural variations of the compound, represented by different formulas, indicating the versatility and potential for further development in the pharmaceutical field. Overall, the patent aims to protect the intellectual property rights associated with the compound and its applications in the treatment of specific medical conditions.
To know more about GlobalData’s detailed insights on Recursion Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.